Tata Elxsi is an engineering research and development services company whose economics rest on an unusually high offshore delivery mix and domain-specific product engineering. It serves three main verticals: Transportation, which is more than 55% of software services revenue; Media & Communications, about 32%; and Healthcare & Life Sciences, roughly 11%, with a small Systems Integration and Support business. The work is embedded in customers' products, from software-defined vehicle architectures and connected-car platforms to OTT systems, telecom network automation, medical devices and regulatory workflows. That makes switching costs high and keeps the work closer to product engineering than to commoditised IT services. Management says the company runs roughly a 25/75 onsite-offshore revenue mix, and that offshore ratio is the structural reason it can defend margins while winning large multi-year programmes against global competition.
The Q2 FY27 result shows why the operating-leverage thesis is alive but not yet proven. Revenue was INR1,055.7 crore, EBITDA INR231.4 crore and EBITDA margin 21.9%, up 70 bps QoQ. Margins expanded despite a company-wide wage increase because 60-70 bps came from cross-currency and 10-20 bps from operating leverage, with most of the Q1 FY27 one-timers gone. All three verticals grew sequentially in constant currency: transportation 2%, media 3.4% and healthcare 3.5%. That is a healthier mix than the prior year, when transportation was the only reliable grower and media and healthcare were contracting or flat. But the margin is still well below the 27-28% historical band, and management gives no numeric target. The task is to convert broad-based sequential growth into sustained revenue growth and then let utilisation and pyramid correction lift margins.
The earnings path depends on three mechanisms. First, new deal ramps. Q2 FY27 disclosed a multi-year telematics and connected-vehicle deal with a leading automotive OEM, a GenAI virtual-assistant deal in media, a renal care home dialysis programme in healthcare, a Sarla Aviation eVTOL collaboration and a global aerospace supplier test-rig engagement. Management says such deals typically take two to three quarters to ramp, so the revenue contribution should build through FY28 rather than immediately. Second, utilisation. It rose to 78% in Q2 FY27 from 74.7% in Q1, with the prior peak at 81-82% and room to improve. Management is also correcting the pyramid over the next half year, moving from senior-heavy teams to trained junior staff, which should support margin over time. Third, the fading of one-off costs. Q1 FY27 carried transition, retention and Chapter 11 provisions; Q2 said most one-timers were gone and salary hikes for the rest of the year are done. If those hold, incremental revenue should carry a higher margin than Q1.
The revenue mix is improving but remains uneven. Transportation is still the largest vertical and the main swing factor. Management was confident on US and India in Q2 FY27, called Japan flattish and Europe soft. Large European deals are in the final shortlist but unsigned, and management says timing could be this quarter or next. Europe was just over 40% of transportation revenue in Q1 FY27, so a prolonged German OEM pause can offset US and India growth. Media has now grown for two consecutive quarters, helped by AI-led wins and consolidation deals, and management expects H2 FY27 better than H1. Healthcare finally turned positive in Q2 FY27 after a long downturn; management says it bottomed last quarter and expects H2 better than H1, with Bayer and Terumo adding geographic and customer diversification. These are credible improvements, but none is yet a quantified multi-year target.
Capital allocation is conservative. The supplied calls disclose no material new physical capex, cash, debt or acquisition in Q2 FY27. Spending is weighted to AI tooling, platforms, people and delivery capacity, and those costs flow through the operating expense line rather than a large capital programme. That supports the operating-leverage thesis because existing capacity can absorb growth: utilisation is 78%, and management says no new physical capacity is needed before the prior 81-82% peak. The trade-off is that AI, cloud and platform investment can pressure near-term margins without a disclosed return metric. Management says customers remain quality- and time-focused rather than demanding AI price cuts, but that is an assertion, not proof. The investment case needs evidence that AI-led wins improve win ratios without compressing pricing.
Management delivery is mixed. The large deal wins announced in April 2025 did ramp and produced transportation growth of 7.7% QoQ in Q3 FY26 and media growth of 11.5% YoY constant currency in Q1 FY27. But the April 2025 promise to grow back in Q1 FY26 missed, margin recovery has been re-dated several times, and the healthcare recovery promised for H2 FY26 arrived only in Q2 FY27. The 75% utilisation target for end-FY26 was not confirmed at the deadline, though utilisation later reached 78%. Aerospace and defence revenue of about INR50 crore in FY26 remains unconfirmed. The correct inference is not that management cannot execute, but that deal-ramp commitments are more reliable than date-specific recovery promises. The Q2 FY27 H2 better-than-H1 expectation should be treated as an open target, not a delivered fact.
The thesis therefore remains operating leverage, with a clear set of falsifiers. The positive case needs H2 FY27 revenue to be better than H1 as management expects, transportation to hold up despite soft Europe, healthcare to sustain its Q2 growth, and margin to continue rising as one-timers fade, wages are absorbed and utilisation moves toward 81-82%. The negative case is that Europe stays unsigned, Q3 furloughs bite, healthcare's rebound proves one quarter, new deal ramps take longer than two to three quarters, and margin stalls because pyramid correction is slow. On the supplied evidence, the business is improving sequentially and the direction of travel is positive, but the quantified proof is still missing. The investment thesis should be judged on whether Q3 and Q4 convert management's H2 expectation into revenue and margin delivery, not on the announcement of new deals alone.
companyname: Tata Elxsi Limited ticker: TATAELXSI sector: IT Services / Engineering R&D Tata Elxsi is an engineering research and development (ER&D) services company, established in 1989, that designs and engineers next-generation products for global manufacturers. It sits at the intersection of design, embedded software, and digital technologies, helping customers build the software-defined, connected, and intelligent products that define modern vehicles, medical devices, and media platforms. ...
Read the full report →none
No formal revenue guidance is given. Management expects H2 FY27 to be better than H1 for Media & Communications and Healthcare and overall except European automotive; Q3 is typically short with fewer working days and possible furloughs. The CFO expects operational leverage and a slightly upward margin trajectory through the rest of FY27, with utilisation at 78% and room to improve, but gives no numeric target.
Guidance maintainedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Tata Elxsi Limited and 4,900+ companies.
5-day free pass. No card required.